Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.46 |
| ▸ | NPY1R | P25929 | 10/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.46 |
| ▸ | NPY2R | P49146 | 6/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leupeptin SCHEMBL13933715 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL11021602 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL583830 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL11596919 | 0.99 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL3308386 | 0.99 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30643187 | 0.99 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL16316642 | 0.94 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| Leupeptin SCHEMBL25361 | 0.94 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11094153 | 0.92 | SMN1; SMN2 (0.42) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL24178182 | 0.92 | BACE1 (0.44) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080213172-A1 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-5153176-A | Substituted lysine-proline-arginine peptide | NITTO BOSEKI CO., LTD. (JP) | 1992-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213172-A1 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES | LAP3, DNPEP, ACE | NPY4R 545/4885NPY1R 590/4885NPY5R 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.